Search Tag: GM-3009
2024 14 Mar
Grant to support IND-enabling toxicology and Phase 1/1b development of novel cardiac-safe ibogaine analog, GM-3009 Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company committed to developing best-in-class, rapid-acting treatments for mental health disorders, today announced that it has been awarded a multi-year $14 million grant...Read more
2024 14 Mar
Grant to support IND-enabling toxicology and Phase 1/1b development of novel cardiac-safe ibogaine analog, GM-3009 Gilgamesh Pharmaceuticals, a clinical-stage neuroscience company committed to developing best-in-class, rapid-acting treatments for mental health disorders, today announced that it has been awarded a multi-year $14 million grant...Read more